News & Events

Category: News

Robert Conklin Joins Vivli as CTO

Robert Conklin has joined Vivli as the Chief Technology Officer. He has more than 25 years of experience in technology.

“I am delighted to welcome Robert to Vivli as we embark on our next growth phase,” said Rebecca Li, Vivli CEO. “With our focus on deploying cutting-edge technologies, Robert’s previous experience as a CTO will be instrumental in driving our innovation efforts forward. He brings a deep understanding of scientific research combined with a forward-thinking approach to technological advancements. I look forward to working with him as Vivli adopts the latest technologies to securely and safely share data, ultimately advancing human health.”

In his role as CTO at Vivli, Conklin leads the strategic direction for technology adoption and integration. His expertise spans a broad spectrum of areas, including data management, clinical trial automation, communication, and data security. He uses this expertise to further advance the Vivli platform, helping the world’s researchers to create new knowledge from the data that our members have shared.

Robert is passionate about leveraging emerging technologies to solve pressing challenges in clinical research to further the advancement of human knowledge. He has been instrumental in driving innovations that improve patient recruitment, streamline regulatory compliance, and ensure data integrity. His contributions have increased the speed, efficacy and safety of clinical trials at scale, and helped to create new knowledge.

Vivli version 3.4 of the platform has been released

Version 3.4 of the Vivli platform has been released and is available to users. The key change with the new version of the platform is users can now submit an enquiry directly on the platform about studies that are not listed in the Vivli search. This change is aimed at supporting researchers and Vivli members so that it is a more seamless process.

“Our members have asked to move the enquiries process to the platform and so we have made this change,” said Julie Wood, Vivli COO. “We think this will allow easier tracking of enquiries. It makes it easier for our members to interact with users and if that study is eligible to be shared, it makes it much easier for a researcher to include it in a data request.”

Other usability features have been added and Vivli how to guides have been updated.

Vivli CEO Rebecca Li to participate in panel discussion for Harnessing the Potential of Patient-Level data in Clinical Trials     

Vivli’s CEO, Rebecca Li, will speak on Day 3 at the Global Clinical Trials: Technology & Innovation webcase series. This online event will take place on May 14-16, 2024. Li will participate as a panelist in a discussion session on ‘Harnessing the Potential of Patient-Level data in Clinical Trials.’

Explore the practical benefits of patient-level datasets in clinical trial as industry experts discuss strategies for implementing fully consented patient data and its impact on trial outcomes. The panel will be held on Thursday, May 16th, 5pm CEST / 4pm BST / 11am EDT. Learn more and register here.

Vivli launches Case Studies to showcase the work of our innovative researchers

Vivli is delighted to announce the launch of our new Case Studies series, designed to highlight the work of researchers around the world who are using the Vivli data repository to produce innovative research and original approaches to diagnosis and treatment for a variety of conditions. Our first compilation of case studies focuses on analyses relevant to Type 2 Diabetes, Rheumatoid Arthritis, cancer, and more.

We’ve developed Case Studies to showcase the variety of valuable projects happening with the support of data-sharing initiatives across the research community. Vivli’s repository of data is built on more than 7,000 research studies across a wide range of research areas, and includes a growing number being shared by individual researchers. This data repository provides a valuable resource for researchers to both share and access data that can be used to accelerate the progress of scientific research.

Are you a researcher whose work uses or produces individual patient data? We’d love to hear from you, whether you’ve got data to share, are interested in exploring our data resources to submit a request for your next project, or would like to see your work included in the Case Studies series.

Contact Vivli

Find out more about how Vivli can support your research

Vivli Webinar: The Potential Impact of Recent U.S. Legal Developments on Data Sharing with China and Other Countries of Concern

Vivli held a webinar to discuss recent developments in data privacy laws and their impact on data sharing.

This webinar was held at 5pm CEST / 11am EDT / 8am PDT on Friday, April 12th

VIEW THE RECORDING

Over the past few weeks there have been significant U.S. executive and congressional actions related to restricting transactions, data transfers, and certain types of contracts with China, other countries of concern (e.g., Russia), and individuals and businesses connected with these countries. Principally, this includes President Biden’s Executive Order (“EO”) on bulk sensitive personal data transfers and the corresponding U.S. Department of Justice Advance Notice of Proposed Rulemaking (“ANPRM”), the unanimous passage by the U.S. House of Representatives of the Protecting Americans’ Data from Foreign Adversaries Act, and the passage of the BIOSECURE Act by a critical Senate Committee.

All three of these developments, if finalized, will have important impacts on the sharing of data and biospecimens with China and certain other jurisdictions that have been labeled “countries of concern.” In this presentation, Ropes & Gray partner, David Peloquin, will walk through these different proposed regulations and legislation, focusing on the implications they each may have for research data sharing. He will also discuss the different timelines and comment periods for the EO and ANPRM, as well as the current status of each of the pending pieces of legislation.

Speaker:

  • David Peloquin, Partner, Ropes & Gray

Learning objectives for this session include:

  • Understanding the basics of the EO, the ANPRM, the BIOSECURE Act and the Protecting Americans’ Data from Foreign Adversaries Act
  • Understanding how each of these proposed regulations or pieces of legislation may affect research data sharing with China and other countries of concern
  • Understanding the potential timelines for implementation of each of these proposed regulations and pieces of legislation

VIEW THE RECORDING

ONO joins Vivli as a Member to Share its Data

“We are delighted to have ONO join as a member of Vivli, particularly given its rich and long history,” said Rebecca Li, Vivli CEO. “We look forward to working with the team at ONO to share their data to meet their data sharing commitments.”

Ono believes that sharing clinical study data and results with researchers, healthcare professionals, and patients contributes to the promotion of scientific studies and medical research, thereby leading to public benefits. Ono shares clinical study data in accordance with the guidelines stipulated in the “IFPMA Principles for Responsible Clinical Trial Data Sharing” presented by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) dated January 15, 2018, as well as in compliance with industry guidelines including Good Publication Practice, applicable laws, and regulation.

For more information about the conditions for accessing ONO data, please visit their member page. For additional information about Membership in Vivli, learn more here.

DNDi joins Vivli to Share its Data

The Drugs for Neglected Diseases initiative (DNDi), has joined Vivli as a member to share its valuable datasets.

“We are delighted to include these important studies from DNDi on Vivli,” said Rebecca Li, Vivli CEO. “Vivli is excited to work with DNDi to make it easy and efficient for researchers to access these data.”

DNDi is an international, not-for-profit research and development organization. It discovers, develops, and delivers treatments for neglected patients around the world. Its treatments are affordable and patient-friendly – and have already saved millions of lives.

“Vivli is a leading data-sharing platform and DNDi is committed to open science,” said Dr Craig Tipple, Medical Director at DNDi. “By working together to share DNDi’s clinical study data, we can optimize the public health and scientific benefits of our research, meet our ethical and scientific obligations for data transparency, and, we hope, accelerate the development of new medicines for neglected diseases.”

For more information about the studies DNDi will share on Vivli, please visit their member page. For additional information about Vivli membership, learn more here.

Vivli Co-Founder Named to 2024 STATUS List

Vivli is delighted to congratulate our co-founder and Board member Dr. Ida Sim on her inclusion in StatNews’ 2024 STATUS List.

The STATUS List recognizes “50 influential people shaping the future of health and life sciences across biotech, medicine, health care, policy, and health tech.”

Dr. Sim is a pioneer in using the power of technology to advance medical research and practice. In addition to her role as professor and chief research informatics officer at the University of California, San Francisco, Dr. Sim has been instrumental in developing key software infrastructure underpinning the digital medicine domain, establishing data-sharing standards, and grappling with the technical challenges of improving access to digital health resources for everyone.

“We are thrilled to hear of Dr. Ida Sim’s inclusion in the STATUS list,” said Rebecca Li, Vivli CEO. “Her efforts and commitment to improving access to medical data have had enormous impacts on health research.”

Read more about the 2024 STATUS List

UCLA joins Vivli to Support its Investigators to share data

“Vivli is delighted to have UCLA join us a member,” said Rebecca Li, Vivli CEO. “We look forward to working with its faculty and staff to support them in their data sharing efforts.”

For more information about the conditions for accessing UCLA data, please visit their member page. For additional information about Membership in Vivli, learn more here.

Vivli Researcher Spotlight: Reusing Data from a Completed Clinical Trial to Inform Guidelines

In a recent study led by Dr. Sarah Nevitt, a senior research associate at the University of Liverpool, a team of researchers examined the effectiveness of various antiepileptic drugs (AEDs) used as monotherapy for people experiencing seizures due to epilepsy. Epilepsy, a common neurological disorder, results from abnormal electrical discharges in the brain, causing recurrent seizures. Typically, around 60% to 70% of individuals with epilepsy achieve longer-term remission, often shortly after beginning treatment with antiepileptic drugs.

Dr. Nevitt and her team sought to compare the performance of 12 different AEDs in terms of treatment failure, remission, and occurrence of first seizures among both children and adults with focal onset or generalized tonic‐clonic seizures. They analyzed data from an extensive collection of clinical trials encompassing more than 22,000 participants, incorporating individual patient data from various studies using a network meta-analysis.

The analysis revealed some key insights. Older drugs like phenobarbitone and phenytoin demonstrated better seizure control for both focal and generalized seizures but had poorer long-term retention rates compared to newer medications such as lamotrigine and levetiracetam. Sodium valproate emerged as the top choice for achieving control and remission of generalized tonic‐clonic seizures, although it might not be suitable for everyone, especially people of childbearing age, due to associated risks.

These findings, published in the Cochrane Library, have already influenced the update of UK guidelines in 2022, providing immediate impact on the treatment of individuals newly diagnosed with epilepsy in the UK. In a recent conversation with Vivli, Dr. Nevitt highlighted that these results are guiding the approach to epilepsy treatment, emphasizing the importance of considering both efficacy and potential side effects when selecting appropriate medications for individuals experiencing seizures.

Interested in finding out more about how access to Vivli’s data repository can help advance your research? Find out more about how to search and request data.